{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:17:49Z","timestamp":1792804669670,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province","award":["18JR2RA033"],"award-info":[{"award-number":["18JR2RA033"]}]},{"name":"The Fundamental Research Funds for the Central Public Welfare research Institutes of the Chinese Academy of Medical Sciences","award":["2019PT320005"],"award-info":[{"award-number":["2019PT320005"]}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"crossref","award":["20JR10RA403"],"award-info":[{"award-number":["20JR10RA403"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After being stagnant for decades, there has finally been a paradigm shift in the treatment of cancer with the emergence and application of immune checkpoint inhibitors (ICIs). The most extensively utilized ICIs are targeting the pathways involving programmed death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4). PD-1, as an crucial immune inhibitory molecule, by and large reasons the immune checkpoint response of T cells, making tumor cells get away from immune surveillance. Programmed cell death ligand-1 (PD-L1) is exceptionally expressed in most cancers cells and approves non-stop activation of the PD-1 pathway in the tumor microenvironment. PD-1\/PD-L1 inhibitors can block the combination of PD-1 and PD-L1, inhibit hostile to regulatory signals, and restore the activity of T cells, thereby bettering immune response. The current researchers assume that the efficacy of these drugs is related to PD-L1 expression in tumor tissue, tumor mutation burden (TMB), and other emerging biomarkers. Although malignant tumors can benefit from the immunotherapy of PD-1\/PD-L1 inhibitors, formulating a customized medication model and discovering biomarkers that can predict efficacy are the new trend in the new era of malignant tumor immunotherapy. This review summarizes the mechanism of action of PD-1\/PD-L1 inhibitors, their clinical outcomes on various malignant tumors, their efficacy biomarkers, as well as predictive markers of irAEs.<\/jats:p>","DOI":"10.1186\/s12935-021-02299-8","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T13:02:59Z","timestamp":1635858179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenwen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caining","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wutang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-7786","authenticated-orcid":false,"given":"Tiankang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"3","key":"2299_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","volume":"14","author":"WB Coley II","year":"1891","unstructured":"Coley WB II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199\u2013220.","journal-title":"Ann Surg"},{"issue":"2","key":"2299_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.0818-9641.2003.01151.x","volume":"81","author":"CR Parish","year":"2003","unstructured":"Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol. 2003;81(2):106\u201313.","journal-title":"Immunol Cell Biol"},{"key":"2299_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jprot.2018.03.033","volume":"191","author":"X Wu","year":"2019","unstructured":"Wu X, Xing X, Dowlut D, et al. Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine. J Proteomics. 2019;191:68\u201379.","journal-title":"J Proteomics"},{"issue":"7637","key":"2299_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"11","key":"2299_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","volume":"12","author":"E Ianchecchi","year":"2013","unstructured":"Ianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12(11):1091\u2013100.","journal-title":"Autoimmun Rev"},{"issue":"328","key":"2299_CR6","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.","journal-title":"Sci Transl Med."},{"issue":"7","key":"2299_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813\u201324.","journal-title":"Int Immunol"},{"issue":"11","key":"2299_CR8","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395.","journal-title":"EMBO J"},{"issue":"8","key":"2299_CR9","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.7314\/APJCP.2012.13.8.4031","volume":"13","author":"OA Elhag","year":"2012","unstructured":"Elhag OA, Hu XJ, Wen-Ying Z, et al. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac J Cancer Prev. 2012;13(8):4031\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"26","key":"2299_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"2299_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"13","key":"2299_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"10105","key":"2299_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362.","journal-title":"Lancet"},{"issue":"26","key":"2299_CR14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"22","key":"2299_CR15","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"2299_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956\u201365.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2299_CR17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483\u201392.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2299_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"19","key":"2299_CR19","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332.","journal-title":"J Clin Oncol"},{"issue":"34","key":"2299_CR20","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2299_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","volume":"4","author":"MJ Frigault","year":"2020","unstructured":"Frigault MJ, Armand P, Redd RA, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122\u20136.","journal-title":"Blood Adv"},{"issue":"10","key":"2299_CR22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","volume":"130","author":"A Badros","year":"2017","unstructured":"Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Blood. 2017;130(10):1189\u201397.","journal-title":"Blood"},{"issue":"17","key":"2299_CR23","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470\u20138.","journal-title":"J Clin Oncol"},{"issue":"36","key":"2299_CR24","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","volume":"35","author":"JS Frenel","year":"2017","unstructured":"Frenel JS, Le Tourneau C, O\u2019Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035\u201341.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2299_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243\u201350.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2299_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711\u20138.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2299_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397\u2013404.","journal-title":"Ann Oncol"},{"issue":"3","key":"2299_CR28","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 2015;10(3):e0121071.","journal-title":"PLoS ONE"},{"issue":"5","key":"2299_CR29","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2299_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-1119.e10.","journal-title":"Cell"},{"issue":"7","key":"2299_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2299_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"2299_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"key":"2299_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","volume":"81","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45\u201351.","journal-title":"Oral Oncol"},{"issue":"3","key":"2299_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322.","journal-title":"Lancet Oncol"},{"issue":"14","key":"2299_CR36","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, et al. Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428\u201339.","journal-title":"J Clin Oncol"},{"key":"2299_CR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R, et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma. Front Oncol. 2019;9:767.","journal-title":"Front Oncol"},{"issue":"23","key":"2299_CR38","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698\u2013704.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2299_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370\u201383.","journal-title":"Cancer Discov"},{"issue":"2","key":"2299_CR40","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6(2):e67\u201378.","journal-title":"Lancet Haematol"},{"issue":"34","key":"2299_CR41","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2299_CR42","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"2299_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan RJ, Hamid O, Gonzalez R, et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019;25(6):929\u201335.","journal-title":"Nat Med"},{"issue":"10030","key":"2299_CR44","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837\u201346.","journal-title":"Lancet"},{"issue":"10066","key":"2299_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.","journal-title":"Lancet"},{"issue":"10031","key":"2299_CR46","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"10122","key":"2299_CR47","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357.","journal-title":"Lancet"},{"issue":"6","key":"2299_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849\u201361.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2299_CR49","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2299_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51\u201364.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2299_CR51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):393\u2013401.","journal-title":"JAMA Oncol"},{"issue":"20","key":"2299_CR52","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"9","key":"2299_CR53","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol. 2017;3(9):e172411.","journal-title":"JAMA Oncol"},{"issue":"9","key":"2299_CR54","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 2020;21(9):1155\u201364.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2299_CR55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","volume":"24","author":"Y Iwai","year":"2017","unstructured":"Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26.","journal-title":"J Biomed Sci"},{"issue":"4","key":"2299_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","volume":"22","author":"TF Nishijima","year":"2017","unstructured":"Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470\u20139.","journal-title":"Oncologist"},{"issue":"1","key":"2299_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"2299_CR58","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","volume":"6","author":"YB Hu","year":"2017","unstructured":"Hu YB, Zhang Q, Li HJ, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6(Suppl 1):S8\u201320.","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"2299_CR59","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346\u201353.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2299_CR60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"9","key":"2299_CR61","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138.","journal-title":"Nat Med"},{"key":"2299_CR62","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3389\/fonc.2020.01649","volume":"10","author":"H Hu","year":"2020","unstructured":"Hu H, She L, Liao M, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer. Front Oncol. 2020;10:1649.","journal-title":"Front Oncol"},{"issue":"19","key":"2299_CR63","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"2299_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31\u201341.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2299_CR65","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/ijms20071607","volume":"20","author":"C Capalbo","year":"2019","unstructured":"Capalbo C, Scafetta G, Filetti M, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy: the Galectin-3 signature in NSCLCs. Int J Mol Sci. 2019;20(7):1607.","journal-title":"Int J Mol Sci"},{"key":"2299_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ctrv.2016.09.019","volume":"50","author":"C Criscitiello","year":"2016","unstructured":"Criscitiello C, Esposito A, Trapani D, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016;50:205\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2299_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12282-016-0698-z","volume":"24","author":"S Burugu","year":"2017","unstructured":"Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24(1):3\u201315.","journal-title":"Breast Cancer"},{"issue":"4","key":"2299_CR68","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1007\/s13277-016-4812-9","volume":"37","author":"ZY Dong","year":"2016","unstructured":"Dong ZY, Wu SP, Liao RQ, et al. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumour Biol. 2016;37(4):4251\u201361.","journal-title":"Tumour Biol"},{"issue":"7","key":"2299_CR69","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Loi S, Garaud S, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873\u201392.","journal-title":"J Clin Invest"},{"issue":"8","key":"2299_CR70","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Di Giacomo","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297\u2013306.","journal-title":"Cancer Immunol Immunother"},{"issue":"21","key":"2299_CR71","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"2299_CR72","doi-asserted-by":"publisher","first-page":"12487","DOI":"10.18632\/oncotarget.23552","volume":"9","author":"JP Wang","year":"2017","unstructured":"Wang JP, Tang YY, Fan CM, et al. The role of exosomal non-coding RNAs in cancer metastasis. Oncotarget. 2017;9(15):12487\u2013502.","journal-title":"Oncotarget"},{"issue":"1","key":"2299_CR73","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-018-0869-y","volume":"17","author":"C Shao","year":"2018","unstructured":"Shao C, Yang F, Miao S, et al. Role of hypoxia-induced exosomes in tumor biology. Mol Cancer. 2018;17(1):120.","journal-title":"Mol Cancer"},{"issue":"1","key":"2299_CR74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4049\/jimmunol.1601464","volume":"198","author":"AP Bally","year":"2017","unstructured":"Bally AP, Tang Y, Lee JT, et al. Conserved region C functions to regulate PD-1 expression and subsequent CD8 T cell memory. J Immunol. 2017;198(1):205\u201317.","journal-title":"J Immunol"},{"issue":"12","key":"2299_CR75","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.bbagrm.2008.08.003","volume":"1779","author":"HY Cho","year":"2008","unstructured":"Cho HY, Lee SW, Seo SK, et al. Interferon-sensitive response element (ISRE) is mainly responsible for IFN-alpha-induced upregulation of programmed death-1 (PD-1) in macrophages. Biochim Biophys Acta. 2008;1779(12):811\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2299_CR76","first-page":"14","volume":"7","author":"T Seto","year":"2019","unstructured":"Seto T, Sam D, Pan M. Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer. Med Sci (Basel). 2019;7(2):14.","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"2299_CR77","doi-asserted-by":"publisher","first-page":"e1412909","DOI":"10.1080\/2162402X.2017.1412909","volume":"7","author":"K Gabrusiewicz","year":"2018","unstructured":"Gabrusiewicz K, Li X, Wei J, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018;7(4):e1412909.","journal-title":"Oncoimmunology"},{"issue":"6382","key":"2299_CR78","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366\u201370.","journal-title":"Science"},{"issue":"6371","key":"2299_CR79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"6371","key":"2299_CR80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"4","key":"2299_CR81","doi-asserted-by":"publisher","first-page":"e1568812","DOI":"10.1080\/2162402X.2019.1568812","volume":"8","author":"A Elkrief","year":"2019","unstructured":"Elkrief A, El Raichani L, Richard C, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(4):e1568812.","journal-title":"Oncoimmunology"},{"issue":"2","key":"2299_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bulcan.2018.08.007","volume":"106","author":"L Nebot-Bral","year":"2019","unstructured":"Nebot-Bral L, Coutzac C, Kannouche PL, et al. Why is immunotherapy effective (or not) in patients with MSI\/MMRD tumors? Bull Cancer. 2019;106(2):105\u201313.","journal-title":"Bull Cancer"},{"issue":"6349","key":"2299_CR83","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"9","key":"2299_CR84","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2299_CR85","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"issue":"7","key":"2299_CR86","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.21037\/tcr-20-1451","volume":"9","author":"L Xiao","year":"2020","unstructured":"Xiao L, Li L, Chen G, et al. The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer. Transl Cancer Res. 2020;9(7):4111\u201320.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"2299_CR87","doi-asserted-by":"publisher","first-page":"e000733","DOI":"10.1136\/jitc-2020-000733","volume":"8","author":"P Correale","year":"2020","unstructured":"Correale P, Saladino RE, Giannarelli D, et al. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1\/PD-L1 immune checkpoint blockade. J Immunother Cancer. 2020;8(1):e000733.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2299_CR88","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.3390\/ijms21124528","volume":"21","author":"D Krijgsman","year":"2020","unstructured":"Krijgsman D, Roelands J, Hendrickx W, et al. HLA-G: a new immune checkpoint in cancer? Int J Mol Sci. 2020;21(12):4528.","journal-title":"Int J Mol Sci"},{"issue":"6375","key":"2299_CR89","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137.","journal-title":"Science"},{"issue":"1","key":"2299_CR90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","volume":"120","author":"S Khan","year":"2019","unstructured":"Khan S, Khan SA, Luo X, et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer. 2019;120(1):63\u20138.","journal-title":"Br J Cancer"},{"key":"2299_CR91","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2019.03.020","volume":"132","author":"J Oyanagi","year":"2019","unstructured":"Oyanagi J, Koh Y, Sato K, et al. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer. 2019;132:107\u201313.","journal-title":"Lung Cancer"},{"issue":"21","key":"2299_CR92","doi-asserted-by":"publisher","first-page":"15542","DOI":"10.18632\/oncotarget.24509","volume":"9","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Sato Y, Tanita K, et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget. 2018;9(21):15542\u201351.","journal-title":"Oncotarget"},{"issue":"9","key":"2299_CR93","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.3390\/cells9091964","volume":"9","author":"P Correale","year":"2020","unstructured":"Correale P, Saladino RE, Giannarelli D, et al. HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis. Cells. 2020;9(9):1964.","journal-title":"Cells"},{"key":"2299_CR94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","volume":"107","author":"O Hasan Ali","year":"2019","unstructured":"Hasan Ali O, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8\u201314.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2299_CR95","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/rheumatology\/key358","volume":"58","author":"LC Cappelli","year":"2019","unstructured":"Cappelli LC, Dorak MT, Bettinotti MP, et al. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58(3):476\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2299_CR96","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12185-016-2101-4","volume":"105","author":"W Munakata","year":"2017","unstructured":"Munakata W, Ohashi K, Yamauchi N, et al. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol. 2017;105(3):383\u20136.","journal-title":"Int J Hematol"},{"issue":"1","key":"2299_CR97","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.244.33","volume":"244","author":"K Sakurai","year":"2018","unstructured":"Sakurai K, Niitsuma S, Sato R, et al. Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab. Tohoku J Exp Med. 2018;244(1):33\u201340.","journal-title":"Tohoku J Exp Med"},{"issue":"18","key":"2299_CR98","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2217\/imt-2019-0160","volume":"11","author":"P Correale","year":"2019","unstructured":"Correale P, Saladino RE, Nardone V, et al. Could PD-1\/PDL1 immune checkpoints be linked to HLA signature? Immunotherapy. 2019;11(18):1523\u20136.","journal-title":"Immunotherapy"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02299-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T13:06:56Z","timestamp":1635858416000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02299-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02299-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"9 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We assure that the material is original and it has not been published elsewhere yet.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"589"}}